You have 9 free searches left this month | for more free features.

Obinutuzumab

Showing 26 - 50 of 229

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Obinutuzumab
  • +6 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Obinutuzumab
  • Changzhou, Jiangsu, China
  • +24 more
Jul 23, 2023

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Scottsdale, Arizona
  • +2 more
Jan 5, 2023

Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis Trial in Boston, Rochester, Philadelphia

Not yet recruiting
  • Granulomatosis With Polyangiitis
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 29, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (RO7227166, Obinutuzumab, Glofitamab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Pasadena, California
  • +14 more
Jan 30, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Follicular Lymphoma Trial in Australia (Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous

Recruiting
  • Follicular Lymphoma
  • Obinutuzumab 25 MG/1 ML Intravenous Solution
  • +2 more
  • Ballarat, Victoria, Australia
  • +3 more
Jul 28, 2022

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

Active, not recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab
  • Bochum, Germany
  • +15 more
Nov 4, 2022

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib and obinutuzumab
  • Milano, MI, Italy
    Strategic Research Program on CLL
Apr 2, 2022

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Lymphoma Trial in China (Obinutuzumab, Glofitamab, Tocilizumab)

Recruiting
  • Lymphoma
  • Obinutuzumab
  • +2 more
  • Beijing, China
  • +6 more
Aug 4, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Leukemia (SLL)
  • Evanston, Illinois
  • +7 more
Sep 9, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Basking Ridge, New Jersey
  • +7 more
Nov 9, 2022

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphoid Leukemia
  • Dresden, Germany
  • +16 more
Nov 8, 2022

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022